Developer docs
API playgroundTry for free, no card

Search company profiles

Extractas Bioscience

Full company profile

uuid000qulw

Namestring
Extractas Bioscience
Legal namestring
Tasmanian Alkaloids Pty Ltd T/A Extractas Bioscience
Company typeenum
Private
Founded yearint
1975
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWestbury, Australia
HQ citystring
Westbury
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
alkaloid raw materials, pharmaceutical botanical extracts, opium poppy processing, controlled substance APIs, GMP pharmaceutical ingredients
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Botanical Ingredients
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Alkaloid Raw Materials (ARM) Sales
TypeOne Time License
Description

Production and sale of alkaloid raw materials including Thebaine, Codeine, Oripavine, and Noscapine to global pharmaceutical manufacturers. These are starting materials for pain-relieving APIs, abuse deterrent formulations, and cough-suppressant medications.

extractas.com.au
2Botanical Extracts and Specialty Ingredients
TypeOne Time License
Description

Customized botanical extraction capabilities and specialty ingredients including poppy seeds (culinary and non-culinary), with products tailored to customer specifications.

extractas.com.au
3Contract Manufacturing Services
TypeProfessional Services
Description

GMP pharmaceutical manufacturing services including analytical services, R&D, regulatory affairs support, and process development for customers from seed to finished products.

extractas.com.au
4Analytical Standards and Regulatory Dossier Support
TypeLicensing Royalties
Description

Supply of analytical standards and 'plug and play' regulatory dossier sections to pharmaceutical customers.

extractas.com.au
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Extractas Bioscience produces and supplies alkaloid raw materials (ARM) — including Thebaine, Codeine, Oripavine, and Noscapine — extracted from its patented Papaver somniferum poppy chemotypes for sale to global pharmaceutical manufacturers. The company also provides customized botanical extraction, synthetic manufacturing, analytical, and regulatory dossier support services on a B2B contract basis, operating GMP-compliant manufacturing at its Westbury, Tasmania facility.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Largest global producer of Thebaine and natural Codeine
+2 more records
Product overview1 text field

Extractas Bioscience is a fully integrated research and manufacturing company offering a portfolio of botanical extracts and purified products for the pharmaceutical industry. The core product line is Alkaloid Raw Materials (ARM) — concentrated poppy straw products including Thebaine, Codeine, Oripavine, and Noscapine — derived from patented poppy chemotypes. The company also produces culinary and non-culinary poppy seeds, medical-grade hand sanitiser, and land/soil conditioner from extraction by-products. Services include botanical extraction capabilities (from kg-lab scale to 35+ tonnes/day), synthetic manufacturing, analytical services with validated methods, and comprehensive regulatory/dossier support. The company operates from Tasmania, Australia, with manufacturing facilities in Westbury.

Product and service13 records
1Alkaloid Raw Materials (ARM)
CategoryPharmaceutical Ingredients
Description

Concentrated poppy straw products extracted from patented Papaver somniferum chemotypes, supplied to global pharmaceutical manufacturers as starting materials for pain-relieving APIs, abuse-deterrent formulations, and cough-suppressant medications.

2Thebaine
CategoryAlkaloid Raw Material
Description

Alkaloid raw material extracted from a patented high-thebaine poppy variety, used as a starting material for pain-relieving and abuse-deterrent Active Pharmaceutical Ingredients (APIs).

3Codeine
CategoryAlkaloid Raw Material
Description

Naturally sourced Codeine produced from a patented high-codeine poppy variety, supplied to global pharmaceutical manufacturers for pain-relief medications.

4Oripavine
CategoryAlkaloid Raw Material
Description

Alkaloid raw material primarily used to produce the Nal family of APIs including Naloxone and Naltrexone, used as abuse-deterrent pharmaceuticals.

5Noscapine
CategoryAlkaloid Raw Material
Description

One of the world's largest produced Noscapine supplies, an alkaloid primarily used for its antitussive (cough-suppressing) effects in pharmaceutical preparations.

6Culinary Poppy Seed
CategoryAgricultural Product
Description

Poppy seeds processed through sieves, aspirators and gravity tables, bulk packaged and delivered to European partners for distribution into confection, spice and bakery industries.

7Non-Culinary Poppy Seed
CategoryIndustrial Agricultural Product
Description

Processed poppy seeds yielding products including biodiesel, furnace fuel, paint oil, and poppy meal used as agricultural fertiliser.

8Medical Grade Hand Sanitiser
CategoryPharmaceutical Product
Description

TGA-registered medical grade hand sanitiser (Ethanol 80%) produced using the company's chemical manufacturing capabilities, compliant with WHO recommended formulation.

9Land and Soil Conditioner
CategoryAgricultural By-Product
Description

Compressed and heat-treated poppy straw husk material (spent marc) distributed as a land and soil conditioner by approved agricultural customers.

10Botanical Extraction Services
CategoryContract Manufacturing Service
Description

Customised botanical extraction capabilities ranging from boutique small-scale extraction (kg-lab scale) through to high-volume biomass extraction exceeding 35 tonnes per day, offered on a contract basis.

11Synthetic Manufacturing Services
CategoryContract Manufacturing Service
Description

Synthetic manufacturing services tailored to customer product requirements and specifications, supporting pharmaceutical customers from seed to finished product.

12Analytical Services
CategoryPharmaceutical Services
Description

Fully validated analytical methods, comprehensive technical packages, and analytical standards supplied to pharmaceutical customers for ARM products.

13Regulatory Support Services
CategoryPharmaceutical Services
Description

Comprehensive DMF and regulatory dossier information, including analytical standards and 'plug and play' regulatory submission sections supplied to pharmaceutical customers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-27
Description

Extractas Bioscience was acquired by Siegfried, a Swiss-listed global Contract Development and Manufacturing Organization (CDMO), as part of a strategic exit by SK Capital Partners. The acquisition included three manufacturing sites (Noramco in Wilmington, Delaware; Purisys in Athens, Georgia; Extractas Bioscience in Tasmania) adding approximately 400 employees. The transaction supports Siegfried's EVOLVE+ strategy and expands its US-based manufacturing capacity.

2Tasmanian Grower Network
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with the most productive and technologically advanced growers across Tasmania and other parts of the world. The success of the 'factory in the field' strategy is born from the partnership nurtured between the Grower base, their highly productive land, and Extractas' Agricultural support team, delivering specific compounds, increased yield and highest quality.

extractas.com.au
3European Poppy Seed Partner
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Long-term partnership with European-based partner for culinary poppy seed distribution. Poppy seeds are bulk packaged and delivered to the European partner who further cleans and blends for distribution into confection, spice and bakery industries globally.

extractas.com.au
Strategic tierMinorTypeStrategic or Co-development Partner
Description

During the COVID-19 pandemic, Extractas partnered with Tasmanian business M2 Logistics to manufacture medical grade Hand Sanitiser and surface cleaning agents for distribution into Australian markets, utilizing Extractas' TGA-registered manufacturing facility and chemical production capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ongoing partnership supporting science education through scholarships (Brian Hartnett Scholarship in Science Teaching, Tasmanian Alkaloids Honours Scholarship in Chemistry, West North-West Bursary) and providing work experience opportunities for students in Agricultural Research and Development.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Macfarlan Smith (Johnson Matthey)
TypeDirect peer
Description

UK-based manufacturer of opiate alkaloids and controlled-substance APIs operating as part of Johnson Matthey's Health division; competes directly with Extractas in the supply of morphine, codeine, and thebaine to global pharmaceutical customers.

TypeBroad incumbent
Description

Swiss-listed global CDMO and Extractas' parent company since May 2026; offers broader pharmaceutical API and finished-dose manufacturing services across multiple chemistries, of which Extractas' botanical/alkaloid work is now one specialized piece.

TypeBroad incumbent
Description

Swiss global CDMO with extensive API and biopharmaceutical manufacturing capabilities; comparable as a broad incumbent serving the same pharmaceutical customer base with overlapping API manufacturing services, though not focused on alkaloid extraction.

4Johnson & Johnson (Janssen)
TypeBroad incumbent
Description

Former owner of Extractas (1982-2016) through its Worldwide Narcotics Franchise and a major buyer of pharmaceutical-grade alkaloids; comparable as a large incumbent pharmaceutical manufacturer with downstream demand for the same controlled-substance APIs Extractas produces.

TypeEmerging player
Description

UK/Ireland-headquartered pharmaceutical services company offering API development, manufacturing, and analytical services; partial overlap with Extractas in custom pharmaceutical manufacturing and analytical/regulatory support services for controlled substances.

TypeDirect peer
Description

Global specialty pharmaceutical company with significant opiate API production and finished-dose pain management products; directly comparable in supplying controlled-substance pharmaceutical ingredients to global drug manufacturers.

TypeDirect peer
Description

US-headquartered producer of opiate alkaloid raw materials and APIs; was acquired alongside Extractas Bioscience by Siegfried in 2026 and is now a sister company with overlapping product portfolio (thebaine, codeine, controlled-substance APIs).

TypeBroad incumbent
Description

Global specialty chemicals company with a Fine Chemistry Services segment producing controlled substances and pharmaceutical intermediates; comparable as a broader chemical manufacturer serving pharma with overlapping regulatory complexity.

TypeDirect peer
Description

Spanish producer of alkaloid raw materials and opiate APIs from poppy cultivation; competes with Extractas in the global alkaloid supply market with comparable extraction capabilities and pharmaceutical-grade output.

TypeDirect peer
Description

US-based API manufacturer specializing in controlled substances and niche pharmaceutical ingredients; acquired together with Extractas by Siegfried in 2026, making it a sister company with comparable botanical/API manufacturing capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Extractas Bioscience

Pharmaceutical Botanical Ingredientsextractas.com.au

Extractas Bioscience firmographics

Firmographics
Name
Extractas Bioscience
Legal name
Tasmanian Alkaloids Pty Ltd T/A Extractas Bioscience
Website
https://extractas.com.au
Company type
Private
Founded year
1975
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Where Extractas Bioscience is headquartered

Location

Headquarters

HQ city
Westbury
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Extractas Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

  1. Alkaloid Raw Materials (ARM) Sales: Production and sale of alkaloid raw materials including Thebaine, Codeine, Oripavine, and Noscapine to global pharmaceutical manufacturers. These are starting materials for pain-relieving APIs, abuse deterrent formulations, and cough-suppressant medications.
  2. Botanical Extracts and Specialty Ingredients: Customized botanical extraction capabilities and specialty ingredients including poppy seeds (culinary and non-culinary), with products tailored to customer specifications.
  3. Contract Manufacturing Services: GMP pharmaceutical manufacturing services including analytical services, R&D, regulatory affairs support, and process development for customers from seed to finished products.
  4. Analytical Standards and Regulatory Dossier Support: Supply of analytical standards and 'plug and play' regulatory dossier sections to pharmaceutical customers.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Extractas Bioscience product offering

Product offering

Core offering

Extractas Bioscience produces and supplies alkaloid raw materials (ARM) — including Thebaine, Codeine, Oripavine, and Noscapine — extracted from its patented Papaver somniferum poppy chemotypes for sale to global pharmaceutical manufacturers. The company also provides customized botanical extraction, synthetic manufacturing, analytical, and regulatory dossier support services on a B2B contract basis, operating GMP-compliant manufacturing at its Westbury, Tasmania facility.

Product overview

Extractas Bioscience is a fully integrated research and manufacturing company offering a portfolio of botanical extracts and purified products for the pharmaceutical industry. The core product line is Alkaloid Raw Materials (ARM) — concentrated poppy straw products including Thebaine, Codeine, Oripavine, and Noscapine — derived from patented poppy chemotypes. The company also produces culinary and non-culinary poppy seeds, medical-grade hand sanitiser, and land/soil conditioner from extraction by-products. Services include botanical extraction capabilities (from kg-lab scale to 35+ tonnes/day), synthetic manufacturing, analytical services with validated methods, and comprehensive regulatory/dossier support. The company operates from Tasmania, Australia, with manufacturing facilities in Westbury.

Differentiator

Problem solved

Functional benefit

Products and services

  • Alkaloid Raw Materials (ARM) Concentrated poppy straw products extracted from patented Papaver somniferum chemotypes, supplied to global pharmaceutical manufacturers as starting materials for pain-relieving APIs, abuse-deterrent formulations, and cough-suppressant medications.
  • Thebaine Alkaloid raw material extracted from a patented high-thebaine poppy variety, used as a starting material for pain-relieving and abuse-deterrent Active Pharmaceutical Ingredients (APIs).
  • Codeine Naturally sourced Codeine produced from a patented high-codeine poppy variety, supplied to global pharmaceutical manufacturers for pain-relief medications.
  • Oripavine Alkaloid raw material primarily used to produce the Nal family of APIs including Naloxone and Naltrexone, used as abuse-deterrent pharmaceuticals.
  • Noscapine One of the world's largest produced Noscapine supplies, an alkaloid primarily used for its antitussive (cough-suppressing) effects in pharmaceutical preparations.
  • Culinary Poppy Seed Poppy seeds processed through sieves, aspirators and gravity tables, bulk packaged and delivered to European partners for distribution into confection, spice and bakery industries.
  • Non-Culinary Poppy Seed Processed poppy seeds yielding products including biodiesel, furnace fuel, paint oil, and poppy meal used as agricultural fertiliser.
  • Medical Grade Hand Sanitiser TGA-registered medical grade hand sanitiser (Ethanol 80%) produced using the company's chemical manufacturing capabilities, compliant with WHO recommended formulation.
  • Land and Soil Conditioner Compressed and heat-treated poppy straw husk material (spent marc) distributed as a land and soil conditioner by approved agricultural customers.
  • Botanical Extraction Services Customised botanical extraction capabilities ranging from boutique small-scale extraction (kg-lab scale) through to high-volume biomass extraction exceeding 35 tonnes per day, offered on a contract basis.
  • Synthetic Manufacturing Services Synthetic manufacturing services tailored to customer product requirements and specifications, supporting pharmaceutical customers from seed to finished product.
  • Analytical Services Fully validated analytical methods, comprehensive technical packages, and analytical standards supplied to pharmaceutical customers for ARM products.
  • Regulatory Support Services Comprehensive DMF and regulatory dossier information, including analytical standards and 'plug and play' regulatory submission sections supplied to pharmaceutical customers.

Quantifiable outcome

  • Largest global producer of Thebaine and natural Codeine
  • +2 more outcomes

Companies that use Extractas Bioscience

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Extractas Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Extractas Bioscience partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

  • Siegfried Holding AGflagshipStrategic or Co-development Partner · 27 January 2026Extractas Bioscience was acquired by Siegfried, a Swiss-listed global Contract Development and Manufacturing Organization (CDMO), as part of a strategic exit by SK Capital Partners. The acquisition included three manufacturing sites (Noramco in Wilmington, Delaware; Purisys in Athens, Georgia; Extractas Bioscience in Tasmania) adding approximately 400 employees. The transaction supports Siegfried's EVOLVE+ strategy and expands its US-based manufacturing capacity.
  • Tasmanian Grower NetworkcoreStrategic or Co-development PartnerPartnership with the most productive and technologically advanced growers across Tasmania and other parts of the world. The success of the 'factory in the field' strategy is born from the partnership nurtured between the Grower base, their highly productive land, and Extractas' Agricultural support team, delivering specific compounds, increased yield and highest quality.
  • European Poppy Seed PartnercoreChannel Partner/ Reseller/ DistributorLong-term partnership with European-based partner for culinary poppy seed distribution. Poppy seeds are bulk packaged and delivered to the European partner who further cleans and blends for distribution into confection, spice and bakery industries globally.
  • M2 LogisticsminorStrategic or Co-development PartnerDuring the COVID-19 pandemic, Extractas partnered with Tasmanian business M2 Logistics to manufacture medical grade Hand Sanitiser and surface cleaning agents for distribution into Australian markets, utilizing Extractas' TGA-registered manufacturing facility and chemical production capabilities.
  • University of TasmaniacoreStrategic or Co-development PartnerOngoing partnership supporting science education through scholarships (Brian Hartnett Scholarship in Science Teaching, Tasmanian Alkaloids Honours Scholarship in Chemistry, West North-West Bursary) and providing work experience opportunities for students in Agricultural Research and Development.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Extractas Bioscience competitors and assessment

Company assessment

Direct peers

  • Macfarlan Smith (Johnson Matthey): UK-based manufacturer of opiate alkaloids and controlled-substance APIs operating as part of Johnson Matthey's Health division; competes directly with Extractas in the supply of morphine, codeine, and thebaine to global pharmaceutical customers.
  • Mallinckrodt Pharmaceuticals: Global specialty pharmaceutical company with significant opiate API production and finished-dose pain management products; directly comparable in supplying controlled-substance pharmaceutical ingredients to global drug manufacturers.
  • Noramco: US-headquartered producer of opiate alkaloid raw materials and APIs; was acquired alongside Extractas Bioscience by Siegfried in 2026 and is now a sister company with overlapping product portfolio (thebaine, codeine, controlled-substance APIs).
  • Alcaliber: Spanish producer of alkaloid raw materials and opiate APIs from poppy cultivation; competes with Extractas in the global alkaloid supply market with comparable extraction capabilities and pharmaceutical-grade output.
  • Purisys: US-based API manufacturer specializing in controlled substances and niche pharmaceutical ingredients; acquired together with Extractas by Siegfried in 2026, making it a sister company with comparable botanical/API manufacturing capabilities.

Broad incumbents

  • Siegfried Holding AG: Swiss-listed global CDMO and Extractas' parent company since May 2026; offers broader pharmaceutical API and finished-dose manufacturing services across multiple chemistries, of which Extractas' botanical/alkaloid work is now one specialized piece.
  • Lonza Group: Swiss global CDMO with extensive API and biopharmaceutical manufacturing capabilities; comparable as a broad incumbent serving the same pharmaceutical customer base with overlapping API manufacturing services, though not focused on alkaloid extraction.
  • Johnson & Johnson (Janssen): Former owner of Extractas (1982-2016) through its Worldwide Narcotics Franchise and a major buyer of pharmaceutical-grade alkaloids; comparable as a large incumbent pharmaceutical manufacturer with downstream demand for the same controlled-substance APIs Extractas produces.
  • Albemarle Corporation: Global specialty chemicals company with a Fine Chemistry Services segment producing controlled substances and pharmaceutical intermediates; comparable as a broader chemical manufacturer serving pharma with overlapping regulatory complexity.

Emerging players

  • Almac Group: UK/Ireland-headquartered pharmaceutical services company offering API development, manufacturing, and analytical services; partial overlap with Extractas in custom pharmaceutical manufacturing and analytical/regulatory support services for controlled substances.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Extractas Bioscience social profiles

Digital presence

Extractas Bioscience compliance and trust

Trust signal

Compliance7 records

Extractas Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Extractas Bioscience leadership team

Management profile

Number of profiles

Profiles6 records

Extractas Bioscience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Extractas Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Extractas Bioscience

What does Extractas Bioscience do?

Extractas Bioscience produces and supplies alkaloid raw materials (ARM) — including Thebaine, Codeine, Oripavine, and Noscapine — extracted from its patented Papaver somniferum poppy chemotypes for sale to global pharmaceutical manufacturers. The company also provides customized botanical extraction, synthetic manufacturing, analytical, and regulatory dossier support services on a B2B contract basis, operating GMP-compliant manufacturing at its Westbury, Tasmania facility.

Is Extractas Bioscience a public or private company?

Extractas Bioscience is a private company. It is classified as corporate owned and is currently operating.

When was Extractas Bioscience founded?

Extractas Bioscience was founded in 1975. It employs 51 to 100 people.

Where is Extractas Bioscience based?

Extractas Bioscience is headquartered in Westbury, Australia, in the Oceania region.

How does Extractas Bioscience make money?

Four revenue lines are on record. Alkaloid Raw Materials (ARM) Sales are the primary driver. The others are botanical Extracts and Specialty Ingredients, contract Manufacturing Services and analytical Standards and Regulatory Dossier Support.

Who are Extractas Bioscience's main competitors?

Direct peers on record are Macfarlan Smith (Johnson Matthey), Mallinckrodt Pharmaceuticals, Noramco, Alcaliber and Purisys. Broad incumbents are Siegfried Holding AG, Lonza Group, Johnson & Johnson (Janssen) and Albemarle Corporation. Almac Group is listed as an emerging player.

Does Extractas Bioscience have an API?

No public API is recorded for Extractas Bioscience.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooSpeciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturingThe HPAPI outsourcing market is dominated by four CDMOs—Lonza, Siegfried, Aspen, and Veranova—with Siegfried currently leading with 28 HPAPI drugs, followed by Lonza with 23 and both Aspen and Veranova tied at 15. Siegfried expanded its leadership position through the May 2026 acquisition of Noramco, adding 13 controlled drugs and two US manufacturing sites in Wilmington, Delaware and Athens, Georgia, along with Extractas Bioscience's Westbury site in Tasmania, Australia. Industry analysis suggests specialization strategies are proving successful for three of the four leading CDMOs, with Siegfried focusing on controlled drugs for central nervous system indications and Lonza concentrating on immunosuppressant and cytotoxic oncology products.Pharmaceutical TechnologySpeciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing - Pharmaceutical TechnologyA market analysis identifies four CDMOs—Siegfried, Lonza, Aspen, and Veranova—as the leading players in outsourced HPAPI (high-potency active pharmaceutical ingredient) manufacturing, with Siegfried leading in HPAPI drug count following its acquisition of Noramco finalized in May 2026. Siegfried's acquisition added two US HPAPI sites and Extractas Bioscience's Tasmanian site, expanding its controlled-drug portfolio to 28 drugs versus Lonza's 23. Lonza has responded by announcing plans to expand ADC payload-linker capabilities at its Visp site in Switzerland by June 2026, positioning itself to compete in the biologic and cytotoxic HPAPI segments.SpecchemonlineSK Capital completes two exitsPrivate investment firm SK Capital Partners has completed two previously announced portfolio company sales: Noramco, Extractas Biosciences, and Purisys were sold to Siegfried, while Phoenix Flavors & Fragrances was sold to Turpaz Industries, with terms undisclosed. SK Capital is retaining Halo Pharmaceuticals, which operates sterile-fill-finish facilities in the US and controlled substance production in Canada, with a sterile injectable manufacturing facility expected online in the second half. Turpaz Industries, which already owns a portfolio of flavors and fragrances companies in North America, stated that Phoenix represents a strong strategic fit for its organization.citybizSK Capital Completes Sale of Noramco, Extractas Biosciences and Purisys to SiegfriedSK Capital Partners has completed the sale of its Noramco Group businesses—Noramco, Extractas Biosciences, and Purisys—to Siegfried Holding AG, marking a strategic exit from the pharmaceutical ingredients and biosciences portfolio within its life sciences investment platform. The transaction terms were not disclosed, and alongside the sale, leadership transitions see Lee Karras and Alan Majewski remaining with SK Capital to guide Halo Pharmaceuticals, the retained contract development and manufacturing organization. The deal underscores ongoing consolidation in the pharmaceutical CDMO sector, where global players are expanding capabilities through acquisitions of specialized manufacturing platforms.boerse.deSiegfried to acquire high-quality small molecules drug substance capacity in the USSiegfried AG has signed binding agreements to acquire the drug substance business of Noramco Group and Extractas Bioscience from an affiliate of SK Capital Partners, encompassing three manufacturing sites with approximately 400 employees: Noramco in Wilmington, Delaware, Purisys in Athens, Georgia, and Extractas Bioscience in Tasmania, Australia. The acquisition, valued below 10 times Enterprise Value/EBITDA, is expected to close later in 2026 pending customary conditions and will be financed through existing and new debt instruments leveraging Siegfried's strong balance sheet. The transaction supports Siegfried's EVOLVE+ strategy by adding highly demanded US-based manufacturing capacity and expanding the company's position in the world's largest pharmaceutical market, combining early-phase development capabilities with controlled substance manufacturing expertise.ContractpharmaSiegfried Acquires Small Molecule Drug Substance Capacity in the U.S.Siegfried, a global CDMO for the pharmaceutical industry, has signed binding agreements to acquire the drug substance business of Noramco Group and Extractas Bioscience from an affiliate of SK Capital Partners. The acquisition includes three manufacturing sites in the U.S. (Wilmington, DE and Athens, GA) and Australia (Tasmania) with approximately 400 employees. The transaction is part of Siegfried's EVOLVE+ strategy to expand its presence in the U.S., the world's largest pharmaceutical market, and strengthen its integrated small-molecule drug substance offering.YahooSK Capital Partners Announces Agreement to Sell Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AGSK Capital Partners has agreed to sell three subsidiaries—Noramco, Extractas Biosciences, and Purisys—to Siegfried Holding AG, a Swiss-listed contract development and manufacturing organization, for an undisclosed amount. The transaction is subject to customary closing conditions and regulatory approvals, with Jefferies serving as lead financial advisor. Upon closing, SK Capital will retain ownership of Halo Pharmaceuticals as a standalone platform focused on finished-dose-form CDMO services in North America.SiegfriedSiegfried to acquire high-quality small molecules drug substance capacity in the USSiegfried (SIX: SFZN), a Swiss pharmaceutical contract development and manufacturing organization (CDMO), has signed binding agreements to acquire the drug substance business of Noramco Group and Extractas Bioscience from an affiliate of SK Capital Partners. The transaction includes three manufacturing sites in the US (Noramco in Wilmington, Delaware; Purisys in Athens, Georgia) and Australia (Extractas Bioscience in Westbury, Tasmania), adding approximately 400 employees. The acquisition, valued below 10x EV/EBITDA and expected to close later this year pending customary conditions, expands Siegfried's presence in the world's largest pharmaceutical market and advances its EVOLVE+ strategy, with the company planning to optimize controlled substance capacity across its US sites.MorningstarSK Capital Partners Announces Agreement to Sell Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AGSK Capital Partners has entered into an agreement to sell Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG, a global Contract Development and Manufacturing Organization listed on the SIX Swiss Exchange. Financial terms of the transaction were not disclosed. Following the close, SK Capital will retain ownership of Halo Pharmaceuticals, a finished-dose-form CDMO operating in the United States and Canada.